Li Huilin – Trademark Portfolio

Entity Type: 01

Li Huilin owns a portfolio of 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), including well-known marks such as SHRUY, DR-MEILIA, and MAGETEFIA. Of these, 3 are registered. The portfolio spans 3 Nice Classification classes, led by Class 8 (Hand Tools) and Class 14 (Jewelry). Headquartered in Shenzhen,Guangdong,.

No.3688,Nanhai Avenue,Nanshan District,

Shenzhen,Guangdong, 518000 , CN

3 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

DR-MEILIA
DR-MEILIA
Registered 2024
SHRUY
SHRUY
Registered 2023
MAGETEFIA
MAGETEFIA
Registered 2014

Trademark Classifications

Li Huilin's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

8
Hand Tools (1 filing)

Hand tools and implements (hand-operated); cutlery; side arms; razors

14
Jewelry (1 filing)

Precious metals and their alloys; jewellery, precious stones; horological instruments

10
Medical Apparatus (1 filing)

Surgical, medical, dental and veterinary apparatus and instruments

Frequently Asked Questions

How many trademarks does Li Huilin have?

Li Huilin has 3 U.S. trademarks filed with the USPTO. Of these, 3 registered.

What trademark classes does Li Huilin file in?

Li Huilin files trademarks across 3 Nice Classification classes. The most active classes are Class 8 (Hand Tools), Class 14 (Jewelry), Class 10 (Medical Apparatus). Class 8 covers hand tools and implements (hand-operated); cutlery; side arms; razors.

What are Li Huilin's most well-known trademarks?

Li Huilin's registered trademark portfolio includes well-known marks such as SHRUY, DR-MEILIA, and MAGETEFIA. These are among 3 currently registered trademarks in the portfolio.

What is Li Huilin's trademark registration success rate?

Li Huilin has a 100% trademark registration rate, with 3 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.